Clinical trial
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
NCT00004144 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00004144 |
|---|---|
| Title | Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer |
| Official title | Phase I Study of Bryostatin 1 and Gemcitabine (Gemzar) |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | bryostatin 1, gemcitabine hydrochloride |
| Enrollment | 36 |
| Start date | May 1, 2000 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: